Search This Blog

Wednesday, June 29, 2022

Can-Fite: Positive Top-Line Results in Phase 3 Psoriasis Study

 

  • Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile

  • Can-Fite has licensing deals for the marketing of Piclidenoson for the treatment of Psoriasis in multiple global regions

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)